https://www.vetarys.com/news/positive-early-canine-data-for-lead-osteoarthritis-program-vtx-304/2026-05-19T19:37:15-04:00https://www.vetarys.com/news/strengthens-scientific-and-advisory-leadership-in-animal-health-and-oncology/2026-05-19T14:06:45-04:00https://www.vetarys.com/news/preclinical-results-for-vtx-301-302-in-cancer-program/2026-05-19T14:10:03-04:00https://www.vetarys.com/news/dual-target-approach-in-osteoarthritis-targeting-pain-and-disease-progression/2026-05-19T19:38:04-04:00https://www.vetarys.com/news/graham-lumsden-and-peter-hanson-launch-vetrix-bio/2026-05-19T19:38:48-04:00https://www.vetarys.com/news/vetrixbio-announces-positive-clinical-data-for-vtx-304-a-first-in-class-bispecific-antibody-for-canine-osteoarthritis/2026-06-05T09:44:51-04:00https://www.vetarys.com/news/vetrixbio-rebrands-as-vetarys/2026-08-01T11:36:51-04:00